March 19 (Reuters) - Novo Nordisk said on Thursday the U.S. Food and Drug Administration has approved a higher dose of its ...

WW International’s (WW) transformation from a purely behavioral weight loss program to offering complementary GLP-1s was reflected in a 42% increase in subscribers and a 32% increase in clinical ...

As use of GLP-1 medications surges, tools like Weight Loss Buddy emerge as critical infrastructure for sustaining ...

A science-based weight loss protocol designed to help men lose fat, preserve muscle, and improve metabolic health ...

The FDA has approved a higher 7.2 mg dose of Novo Nordisk’s Wegovy (Wegovy HD) for chronic weight management in adults with ...

How the rush to release affordable and accessible versions of weight loss drugs could reshape the fight against ‘diabesity’ ...

A coalition of Hispanic health and public policy organizations is pushing for New Mexico’s Medicaid program to broaden its ...

People taking new prescription weight loss medications may be missing key nutrients they need, according to a new study.

The FDA has approved a new higher-dose version of injectable semaglutide (Wegovy HD, Novo Nordisk) for both weight loss and ...

Federal regulators on Thursday approved a new higher-dose version of the blockbuster obesity drug Wegovy that may help users ...

Consumers filed over 200 complaints with some telemedicine companies for misleading customers about costs of weight loss ...

Being overweight or obese is associated with numerous health problems and about 75% of American adults are overweight or ...